Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cerivastatin.

A Cheng-Lai1

  • 1Department of Pharmacy, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467, USA.

Heart Disease (Hagerstown, Md.)
|December 1, 2001
PubMed
Summary
This summary is machine-generated.

Cerivastatin effectively lowers cholesterol and triglycerides in patients with hyperlipidemia. The 0.4 mg dose significantly reduces LDL cholesterol and triglycerides, enhancing its competitive profile among HMG-CoA reductase inhibitors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A comparison of direct thrombin inhibitors in the treatment of Heparin-Induced Thrombocytopenia: a single institution experience.

Journal of thrombosis and thrombolysis·2008
Same author

Cardiovascular drug therapy in the elderly.

Heart disease (Hagerstown, Md.)·2001
Same author

Orlistat.

Heart disease (Hagerstown, Md.)·2001
Same author

Rosiglitazone: an agent from the thiazolidinedione class for the treatment of type 2 diabetes.

Heart disease (Hagerstown, Md.)·2001
Same author

Cardiovascular drug highlight: hirudin.

Heart disease (Hagerstown, Md.)·2001
Same journal

Ximelagatran: a new oral anticoagulant.

Heart disease (Hagerstown, Md.)·2003
Same journal

Long-term (2-4 year) weight reduction with metformin plus carbohydrate-modified diet in euglycemic, hyperinsulinemic, midlife women (Syndrome W).

Heart disease (Hagerstown, Md.)·2003
Same journal

A comparison of humanistic qualities among medical students, residents, and faculty physicians in internal medicine.

Heart disease (Hagerstown, Md.)·2003
Same journal

Effect of carotid angioplasty-stenting on short-term mortality and stroke.

Heart disease (Hagerstown, Md.)·2003
Same journal

Evidence for the extrapulmonary localization of inhaled nitric oxide.

Heart disease (Hagerstown, Md.)·2003
Same journal

Timing and duration of administration are crucial for antiinfarct effect of AMP 579 infused at reperfusion in rabbit heart.

Heart disease (Hagerstown, Md.)·2003
See all related articles

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Cerivastatin is a potent HMG-CoA reductase inhibitor with favorable pharmacokinetics.
  • It is used for primary hypercholesterolemia and mixed dyslipidemia.

Purpose of the Study:

  • To evaluate the efficacy of cerivastatin in lowering cholesterol and triglycerides.
  • To highlight the impact of the newly approved 0.4 mg dose.

Main Methods:

  • Clinical trials were conducted to assess cerivastatin's lipid-lowering effects.
  • Dose-dependent efficacy was analyzed for total cholesterol, LDL cholesterol, and triglycerides.

Main Results:

  • Cerivastatin demonstrated dose-dependent reductions in total and LDL cholesterol.
  • The 0.4 mg daily dose lowered LDL cholesterol by approximately 35% and triglycerides by 28% (in patients with baseline TG > 300 mg/dL).

Related Experiment Videos

  • Triglyceride reduction showed a strong correlation with baseline triglyceride levels.

    • Conclusions:

    • Cerivastatin is an effective treatment for hypercholesterolemia and mixed dyslipidemia.
    • The 0.4 mg dose enhances cerivastatin's efficacy, making it more competitive in the statin market.